TTP-8307
TTP-8307 is a potent inhibitor of the replication of several rhino- and enteroviruses. TTP-8307 inhibits coxsackievirus B3 (CVB3; EC50=1.2 μM) and poliovirus by interfering with the synthesis of viral RNA. TTP-8307 exerts antiviral activity through oxysterol-binding protein (OSBP) [1][2].
Product Specifications
CAS Number
950225-08-8
UNSPSC
12352005
Target
DNA/RNA Synthesis; Enterovirus; HCV
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/ttp-8307.html
Purity
99.90
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N[C@@H](C1=CC=C(F)C=C1)C)C2=CC=CC(C3=CN=C(C4=CC5=C(C=N4)C=CC=C5)N3)=C2
Molecular Formula
C27H21FN4O
Molecular Weight
436.48
References & Citations
[1]De Palma AM, et al. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother. 2009 May;53 (5) :1850-7.|[2]Albulescu L, et al. Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307. Antiviral Res. 2017 Apr;140:37-44.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400656-100 1x 100 µL
TNF alpha (TNF656), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC942060-100 1x 100 µL
PAX5 / BSAP (Early B-Cell Marker) (PAX5/2060), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 